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InTroDuCTIon
In patients with non-smallcell lung cancer (NSCLC), 
administration of curative radiation therapy (RT) results in 
radiation associated lung injury (RALI), which consists of 
radiation pneumonitis in the acute phase and pulmonary 
fibrosis in the late phase.1 Where underlying lung function 
is abnormal, RALI risks vital loss of respiratory function 
and the morbidity of debilitating dyspnoea. Therefore, 
escalation of radiation dose to increase the probability of 
tumour cell death also must be traded against the rising 
probability of RALI.2 Although regional variation in lung 
function3 is documented, treatment planning simplistically 
considers anatomic lung as a uniform structure. This is 
because the incidence of symptomatic early phase radiation 
pneumonitis and later pulmonary fibrosis increase with the 
anatomic volume of lung that is irradiated and the dose (in 
Gy) delivered4; mean lung dose (MLD) and the fractional 
volume (%) of lungs receiving greater than an indicated 
dose are predictive of RALI.1,5,6
More recently, functional image-guided RT planning 
for normal lung avoidance using single photon emission 
CT (SPECT),7 18-fluodeoxy glucose positron emission 
tomography (18FDG PET) or hyperpolarized gas MRI have 
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objectives: In non-small cell lung cancer (NSCLC) 
patients, to establish whether the fractional volumes of 
irradiated anatomic or perfused lung differed between 
those with and without deteriorating lung function or 
radiation associated lung injury (RALI).
Methods: 48 patients undergoing radical radiotherapy 
for NSCLC had a radiotherapy-planning CT scan and 
singlephoton emission CT lung perfusion imaging 
(99mTc-labelled macroaggregate albumin). CT defined 
the anatomic and the singlephoton emission CT 
scan (co-registered with CT) identified the perfused 
(threshold 20 % of maximum) lung volumes. Fractional 
volumes of anatomic and perfused lung receiving more 
than 5, 10, 13, 20, 30, 40, 50 Gy were compared between 
patients with deteriorating (>median decline) vs stable 
(<median decline) forced expiratory volume in 1 s (FEV1) 
and between those with and without RALI (assessed by 
Common Toxic Criteria for Adverse Events) radiation 
pneumonitis and pulmonary fibrosis scores.
results: Fractional volumes of anatomic and perfused 
lung receiving more than 10, 13 and 20 Gy were signif-
icantly higher in patients with deteriorating vs stable 
FEV1 ( p = 0.005, 0.005 and 0.025 respectively) but did 
not differ for higher doses of radiation (>30, 40, 50 Gy). 
Fractional volumes of anatomic and perfused lung 
receiving > 10 Gy best predicted decline in FEV1 (Area 
under receiver operating characteristic curve (Az = 
0.77 and 0.76 respectively); sensitivity/specificity 75%/81 
and 80%/71%) for a 32.7% anatomic and 33.5% perfused 
volume cut-off. Irradiating an anatomic fractional volume 
of 4.7% to > 50 Gy had a sensitivity/specificity of 83%/89 
% for indicating RALI (Az = 0.83).
Conclusion: A 10–20 Gy radiation dose to anatomic or 
perfused lung results in decline in FEV1. A fractional 
anatomic volume of >5% receiving >50 Gy influences 
development of RALI.
advances in knowledge: Extent of low-dose radiation 
to normal lung influences functional respiratory decline.
2 of 9 birpublications.org/bjr Br J Radiol;92:20190184
BJR  Weller et al
Although SPECT perfusion studies have long been investigated 
as predictor of RALI, perfusion-weighted threshold values have 
varied between studies and confirmatory data is required.7,9,14–18 
99mTc labelled macroalbumin aggregate (MAA) SPECT imaging 
(using aggregates 10–150 µm in diameter that accumulate in 
pulmonary capillaries with a regional concentration that is 
proportional to first pass pulmonary blood flow) provides a 
quantitative measure of regional variation in pulmonary perfu-
sion.19–21 The technique may be exploited to assess toxicity based 
on radiation dose to perfused rather than anatomic lung. Two 
studies have specifically compared functional SPECT imaging 
with conventional CT imaging for predicting RALI.7,22 Both 
showed that functional SPECT imaging could better predict 
radiation pneumonitis in lung cancer patients treated with cura-
tive radiotherapy, although the differences between predictive 
metrics did not reach statistical significance. This study there-
fore aimed to establish whether fractional volumes of irradiated 
perfused lung identified on SPECT imaging differed between 
those with and without deteriorating lung function (as measured 
by forced expiratory volume at 1 s, FEV1) or RALI (using 
Common Toxic Criteria for Adverse Events (CTCAE) radiation 
pneumonitis and pulmonary fibrosis scores).23 The findings were 
compared with equivalent data for irradiated fractional anatomic 
lung volumes.
MeThoDS
Between 18 May 2010 and 26 May 2015, this prospective, insti-
tutional review board approved, single-centre trial recruited 
58 patients aged 45–87 years old (Table  1). All gave written 
informed consent. Patients had histologically confirmed locally 
advanced non-resectable NSCLC (all subtypes) suitable for 
radical radiotherapy (Stages I–IIIb). 10 were withdrawn prior 
to radiotherapy (6 changed treatment plan, 1 opted for surgery 
prior to radiotherapy, 1 unable to tolerate the study imaging, 1 
withdrew consent, 1 missed the SPECT perfusion scan appoint-
ment). The 48 patients enrolled underwent a planning CT 
thorax scan (thoracic inlet to below the diaphragm) with intra-
venous contrast as clinically indicated. The scan was performed 
in breath-hold with the use of the an active breathing control 
(ABC) device,24 or a four-dimensional (4D) scan was acquired 
in free-breathing if the ABC device was not tolerated. Within a 
4 h period, the patient underwent a lung SPECT perfusion scan.
RT planning was routine; patients received either conformal 
or intensity modulated RT as clinically indicated (60–66 Gy 
in 2 Gy fractions over 6.5 weeks) or accelerated hypofraction-
ated regimen (55 Gy in 20 daily fractions over 4 weeks). Gross 
target volume (GTV) or internal target volumes (ITVs) were 
created for ABC and 4DCT scans respectively. For the 4DCT, the 
maximum inhale and exhale phases (0 and 50% as defined with 
our CT scanner) were used for GTV definition. These were then 
combined on the average CT plan to generate an ITV. Treatment 
planning was performed on the 4DCT average scan reconstruc-
tion. Anatomic lung volumes were delineated as a single volume 
using CT lung windows to ensure inclusion of all parenchyma 
from apices to bases, including regions of collapse or consoli-
dation and ensuring that the GTV/ITV, trachea and proximal 
bronchial tree were excluded from this volume. No clinical 
target volume (CTV) margin was required and GTV-planning 
target volumes (PTVs) margins for ABC scans were circumfer-
entially 1 cm. For 4DCT scans, margins for ITV to PTV were 
0.5 mm axially and 0.7 mm craniocaudally. Three-dimensional 
conformal plans were generated using the Pinnacle3 treatment 
planning system (Philips Medical Systems, Best, NL), using a 
collapsed cone convolution calculation algorithm for dose calcu-
lation. All plans were optimized to comply with the following 
dose-volume constraints: MLD <20 Gy; V20 <35%; and in some 
cases V5 <60%. This was performed without reference to the 
functional SPECT data.
Table 1. Patient characteristics for n = 48 patients undergoing 
99mTc-MAA SPECT perfusion prior to radiotherapy, docu-
menting demographics, tumour location, lung volumes and 
planning target volumes
Characteristic
SPECT CT pre RT, plus 
CTCAE (n = 44) or 
FEV1 (n = 41) outcome 
data
Age (yr)









Squamous cell carcinoma 18
Unspecified NSCLC, large cell or not 
recorded
6





Previous smoker (never smoked) 26 (2 never smoked)
Tumour location
Upper lobe 25
Middle lobe or lingula 10
Lower lobe 8
RT volumes
PTV (cm3) mean [sd; range] 167.3 [116.2; 23–757.5]
Total lung volume (cm3) median [sd; 
range]
4790 [1279; 2638–7735]
CTCAE, Common Toxic Criteria for Adverse Events; 
MAA,macroalbumin aggregate; NSCLC, non-small cell lung cancer; 
PTV, planning target volume; RT, radiation therapy; sd,standard 
deviation.
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41 patients had FEV1 and forced vital capacity (FVC) measured 
at least once following therapy (no spirometry data were 
recorded in the other 7) and 40 patients had CTCAE recorded 
at either 3 or 6 months post-RT. The eight patients with missing 
CTCAE data at 3 and 6 months comprised 5 who died, one who 
had surgery within 1 month of radiotherapy and one patient who 
missed their trial follow-up appointments.
SPeCT SCannIng anD IMage PoST-
ProCeSSIng ProToColS
Patients were positioned in the radiotherapy position (supine 
with arms above their heads), on the γ camera couch, prior to 
intravenous injection of 200 megabecquerels (MBq) of 99mTc-
MAA. SPECT images were acquired with a dual-headed γ camera 
(Phillips Medical Systems Forte or Siemens Intevo), with a low 
energy high resolution collimator at discrete 3° angular intervals 
with each camera head rotating through 180° (64 projections at 
20 s per camera view using a 128 × 128 matrix, pixel size 4.67 
mm). Data were reconstructed using the ordered subset expecta-
tion maximization (OSEM) algorithm on a clinical workstation 
(Hermes Medical Solutions Incorporated, Stockholm, Sweden).
SPECT perfusion data were anatomically co-registered and 
fused with the radiotherapy planning CT (Syngo, Siemens 
Medical Solutions, Forchheim, Germany). Automated image 
anatomic co-registration was applied. Mis-registrations were 
manually adjusted by an experienced radiologist (AW) and took 
into account differences in breath-hold between SPECT (free 
breathing) and RT planning (breath-hold in moderate deep 
inspiration inspiration). Where discrepancy existed in the level 
of pulmonary inflation between the RT planning CT and SPECT 
images, the lung apices, the hilae and any perfusion defect asso-
ciated with the primary tumour were used as reference points. 
These represented structures that were either relatively fixed in 
position with inspiration (lung apices in contra distinction to 
the diaphragm), or were unlikely to contain radiotracer activity 
due to first-pass uptake within the pulmonary capillary bed (e.g. 
tumour and hilar structures).
"Perfusion volumes" were defined using a two-step process. 
First, all voxels within both lungs that contained tracer activity 
were contoured within a single boundary. Second, "perfusion 
volumes" were generated within this boundary by setting a 
threshold constraint to include only those voxels that contained 
equal to or more than a defined proportion of maximum voxel 
perfusion count. A 20% threshold of maximum voxel perfusion 
count (p20) was used.14 At higher perfusion thresholds (25, 
30, 40 and 50% of maximum voxel perfusion count), discrep-
ancies between anatomic and perfused lung volumes as a result 
of differences in levels of inspiration during data acquisition led 
to more severe SPECT/planning CT image mis-registration. As 
reported by prior groups, p20 was therefore selected as the most 
robust measure of perfused lung. Perfusion volumes generated 
using the co-registered SPECT and RT planning data sets were 
imported into the Pinnacle3 RT-treatment planning platform 
(Figure 1).
Dose–volume histograms were calculated for volume of anatomic 
(a) and perfused (p20) lung receiving more than 5, 10, 13, 20, 30, 
40, 50 Gy and MLD (denoted as aV5, aV13, aV20, aV30, aV40, 
aV50, aMLD and pV5, pV10, pV13, pV20, pV30, pV40, pV50, 
pMLD respectively).
ClInICal aSSeSSMenTS
Clinical assessment was carried out at baseline and 1, 3, 6, 9, 12, 
15, 18 and 24 months post-treatment using spirometry (FEV1). 
Radiation associated lung injury was assessed at all follow-up 
time-points, using the CTCAE v. 3.0 grading system for char-
acterizing radiation induced pneumonitis (early) or pulmonary 
fibrosis (late), depending on the timing of follow-up assessment. 
Figure 1. Functional perfusion volumes and RT isodose contours: axial (a) and coronal (b) images through a right hilar tumour. 
The dark blue volume encompassing both lungs represents anatomical lung volume ("lung volume – PTV"). The smaller volumes 
contained within this represent the "perfusion volumes": Red = p20 (voxels with ≥20% of maximum voxel intensity); Green = p25; 
Pale blue = p30; Yellow = p40; Magenta = p50. The RT iso-dose contours are overlaid on these volumes to demonstrate the dose 
delivered to a right hilar and upper lobe tumour in this patient. PTV contour is not included in this image. PTV,planning target 
volumes; RT, radiation therapy.
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In the early phase (upto and including 6 months following end 
of RT), CTCAE v. 3.0 radiation pneumonitis was used and in the 
late phase (9 months and beyond), pulmonary fibrosis scoring 
was applied. Radiation associated pneumonitis and fibrosis are 
collectively referred to as RALI.
Under CTCAE v. 3.0, radiation-induced symptoms (dyspnoea, 
cough, pain and low-grade fever) plus distinctive radiological 
changes on CT or chest X-ray were evaluated. A distinction was 
made between "mild" (Grade 0–1) and "moderate–severe" (Grade 
2–5) radiation pneumonitis and pulmonary fibrosis, as grades ≥2 
are defined by symptoms that limit activities of daily living and/
or require medical intervention (early phase–radiation pneumo-
nitis) and moderate hypoxaemia (late phase–pulmonary fibrosis). 
Worst CTCAE radiation pneumonitis grade was recorded at 3 
and 6 months following RT (when RT-induced pneumonitis is 
expected to peak). Mann–Whitney U-tests were used to assess 
for a difference in dose–volume parameters between "radiation 
pneumonitis" and "no radiation pneumonitis" groups.
DaTa analySIS
Data were analysed in Excel and Graph-pad Prism (v. 8). A dose 
parameter of V20 was applied to SPECT-perfused lung volumes 
(as an independent organ-at-risk), to discriminate between 
"RALI" and "no RALI" groups on CTCAE v. 3.0. The fractional 
change in FEV1 after radiotherapy was calculated:
ΔFEV1 (%) = 100 (FEV1postRT – FEV1Baseline)/FEV1Baseline
Greater than or less than median FEV1 fractional change 
discriminated patients with deteriorating vs stable respiratory 
function. Data from all follow-up visits were collated to describe 
"RALI," graded according to CTCAE v. 3.0—early phase radia-
tion pneumonitis and late phase pulmonary fibrosis.
STaTISTICal analySIS
Fractional lung volumes defined by anatomic and perfused lung 
receiving >5, 10, 13, 2, 30, 40 and 50 Gy were compared using 
one-way analysis of variance (ANOVA).
Differences in anatomic and perfused lung dose-volume parame-
ters were evaluated between patients with Deteriorating vs Stable 
FEV1 using the independent Student’s t-test. Receiver operating 
characteristic (ROC) analyses estimated the ability of anatomical 
and perfused lung dose–volume parameters to predict deteriora-
tion in FEV1. Similar analyses were undertaken between those 
with and without radiation pneumonitis and with and without 
RALI (Mann–Whitney U statistic). Bonferroni correction was 
used to set the level of significance as p = 0.00625 (=0.05/8). This 
is based on the assumption of no second-order interactions, and 
potentially sets excessively stringent requirements for statistical 
significance.25
reSulTS
Comparison of anatomic and perfused lung 
volumes and dose–volume parameters
The volumes of anatomic and perfused lung receiving 5, 10, 13, 
20, 30, 40 and 50 Gy dose thresholds are given in Table 2 and 
illustrated as boxplots in Figure 2.
Table 2. Absolute volumes of anatomic and perfused lung (p20) receiving ≥5, 10, 13, 20, 30, 40 and 50 Gy
Volume
Anat vol (ml) 
mean (sd)
p20 vol (ml) 
mean (sd)
p25 vol (ml) 
mean (sd)
p30 vol (ml) 
mean (sd)





Total 4723 (1244) 2331 (571) 1936 (489) 1590 (429) 1006 (316) 556 (218)
≥5 Gy 2132 (305) 1213 (236) 1006 (207) 824 (179) 517 (125) 276 (75)
≥10 Gy 1519 (189) 865 (153) 709 (132) 573 (113) 348 (76) 181 (43)
≥13 Gy 1228 (131) 679 (106) 550 (89) 438 (75) 257 (48) 128 (25)
≥20 Gy 824 (58) 442 (48) 351 (39) 273 (32) 153 (19) 73 (10)
≥30 Gy 544 (27) 292 (24) 227 (19) 174 (15) 93 (9) 43 (4)
≥40 Gy 342 (13) 196 (13) 150 (10) 113 (8) 59 (4) 27 (2)
≥50 Gy 152 (3) 110 (4) 81 (3) 59 (2) 28 (1) 11 (0.4)
NB Differences between anatomic volumes and p20 volumes at all dose levels were significant (p<0.0001 after Bonferroni correction).
Figure 2. Boxplot of the anatomic and perfused lung volumes 
delineated using the RT planning and SPECT perfusion imag-
ing respectively. Perfused volumes are all significantly smaller 
than the anatomic volumes (at all thresholds), with the biggest 
change occurring between the anatomic and the p20 volume. 
The p50 volume is the smallest for each patient. RT,radiation 
therapy; SPECT, single photon emission CT.
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Pairwise differences confirmed that the anatomic volume was 
significantly larger than the perfused volume across the entire 
cohort; the biggest difference occurred between anatomic and 
perfused lung volumes receiving >20 Gy (aV20 vs pV20), for all 
dose thresholds, (p < 0.0001, Table 2).
Effect of pulmonary dose-distribution on 
spirometry
Fractional volumes of both anatomic and perfused lung 
receiving >10 and 13 Gy were significantly larger in patients 
with deterioration in FEV1 (greater than median FEV1 change) 
compared with those who had stable FEV1 (p ≤ 0.005, Tables 3 
and 4). This indicates that low dose radiation to both anatomic 
and perfused lung results in subsequent reduction in respiratory 
function. The fractional volumes of anatomic and perfused lung 
receiving higher doses of radiation (30, 40 and 50 Gy) did not 
differ between these groups, indicating that the higher doses of 
radiation closer to or within the planning target volume did not 
result in subsequent deterioration of FEV1. Fractional volumes 
of anatomic and perfused lung were not significantly different 
between patients with “deteriorating” FVC (greater than median 
FVC change) or “stable” FVC at any dose threshold.
ROC analysis for the fractional anatomic and perfused lung 
volumes receiving >10 Gy (aV10 and pV10 respectively) 
provided the best predictors of decline in FEV1 following radio-
therapy, compared with other dose thresholds (Figure  3). The 
sensitivity and specificity of aV10 for predicting deterioration in 
FEV1 at a threshold of 32.7% was 75 and 81% respectively (AUC 
= 0.77); for pV10, a threshold of 33.5% gave a sensitivity of 80% 
and specificity of 71.4% (AUC = 0.76).
Effect of pulmonary dose distribution on CTCAE 
outcome
CTCAE scores at 3 and/or 6 months (measure of radiation pneu-
monitis) was available in 40 patients, and at any stage during 
the longer 24 month follow-up period (either early phase radia-
tion pneumonitis or late phase pulmonary fibrosis as a measure 
Table 3. Summary of anatomic lung dose-volume parameters in patients that experienced greater than ("Deteriorating FEV1") and 
less than ("Stable FEV1") the median percentage decline in FEV1 at different radiotherapy dose thresholds (V5-50) and for MLD
% Anatomic volume
"‘Stable 













V5 39.6 47.4 7.9 0.093 0.66
V10 25.9 36.7 10.8 0.005** 0.77
V13 20.8 30.1 9.3 0.005** 0.76
V20 14.5 19.5 5.1 0.025 0.70
V30 9.9 12.4 2.5 0.129 0.65
V40 6.4 7.6 1.2 0.313 0.61
V50 2.7 3.5 0.8 0.211 0.66
MLD (cGy) 897 1127 229 0.040 0.69
AUC, area under the curve; MLD, mean lung dose; ROC, receiver operating characteristic.
Results that reach statistical significance after applying the Bonferroni correction (significance level 0.05/8 = 0.00625) are marked**.
Table 4. Summary of functional lung dose-volume parameters in patients that experienced greater than ("Deteriorating FEV1") and 

















p20V5 43.8 56.0 12.2 0.050 0.68
p20V10 27.2 43.6 16.4 0.003** 0.76
p20V13 21.3 35.0 13.6 0.005** 0.74
p20V20 14.7 22.1 7.4 0.033 0.68
p20V30 10.5 13.8 3.3 0.213 0.60
p20V40 7.5 8.9 1.3 0.520 0.56
p20V50 4.5 4.8 0.3 0.797 0.55
p20MLD (cGy) 987 1310 323 0.052 0.67
AUC, area under the curve; MLD, mean lung dose; ROC, receiver operating characteristic.
Results that reach statistical significance after application of the Bonferroni correction (significance level 0.05/8 = 0.00625) are marked with**.
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of RALI) in 44 patients. The latter broader definition of RALI 
has been used in previous similar analyses in the literature and 
increased the number of RT toxicity events in our study cohort 
from n = 4 (radiation pneumonitis) to n = 6 (RALI).7
Of the 40 patients in whom pre-radiotherapy SPECT scanning, 
RT dose-distribution and CTCAE follow up at 3–6 months were 
available, four experienced a worst CTCAE grade of 2–5 (radi-
ation pneumonitis) compared with 36 in whom the worst grade 
did not exceed 1 ("no radiation pneumonitis"). All 4 were Grade 
2 pneumonitis (symptomatic and interfering with activities of 
daily living, but not requiring oxygen). None experienced early 
phase CTCAE ≥3 within 6 months. There was no significant 
difference between the early phase "radiation pneumonitis" and 
"no radiation pneumonitis" groups in the percentage of anatomic 
(p = 0.24) or perfused (p = 0.78) lung volumes that received ≥20 
Gy (Table 5).
Of the 44 patients in whom SPECT scanning, RT dose-distri-
bution and CTCAE follow up at 0–24 months were available, 6 
experienced a worst CTCAE grade of 2–5 ("RALI"), compared 
with 38 in whom the worst grade did not exceed 1 ("no RALI"). 
In the six patients with RALI, four had experienced early phase 
Grade 2 pneumonitis, one experienced late phase CTCAE Grade 
3 (50–75% of lung volume fibrotic on imaging), and one late 
phase CTCAE Grade 5 (death). The perfused lung volumes were 
not significantly different between the "RALI" and "no RALI" 
groups at any dose threshold. The fractional volume of anatomic 
lung receiving ≥50 Gy was significantly different between the 
"RALI" and "no RALI’" groups. ROC analysis showed that when 
4.7% of the anatomic lung volume received >50 Gy, the sensi-
tivity and specificity for predicting subsequent RALI was 83 and 
89% respectively (Figure 4).
Comparison of spirometry with CTCAE
No significant difference in ΔFEV1 following RT was demon-
strated between the CTCAE defined "RALI" and "no RALI" 
groups (Mann–Whitney p-value = 0.99). No significant differ-
ence was seen between the CTCAE defined "RALI" and "no 
Figure 3. ROC of aV10 (dose distribution within anatomic lung, (a) and pV10 (perfused lung, (b) for predicting decline in FEV1 
greater than the median. Area under the ROC (Az) = 0.77 in a and 0.76 in b. ROC, receiver operating characteristic.
Table 5. Summary of p20 functional lung dose-volume parameters in patients classified as RALI (n = 6) on CTCAE and those clas-















p20V5 55.7 50.9 4.8 0.472 0.60
p20V10 40.0 36.1 3.9 0.514 0.59
p20V13 30.7 26.0 4.8 0.514 0.59
p20V20 22.1 15.9 6.2 0.582 0.57
p20V30 18.0 9.8 8.3 0.472 0.60
p20V40 12.2 6.5 5.7 0.431 0.61
p20V50 6.8 3.5 3.2 0.514 0.59
p20MLD
(cGy)
1356 1028 328 0.431 0.61
AUC, area under the curve; CTCAE, Common Toxic Criteria for Adverse Events; MLD, mean lung dose; RALI, radiation-associated lung injury; 
ROC, receiver operating characteristic.
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RALI" groups in terms of either their ∆FVC (Mann–Whitney 
p-value = 0.97) or ∆(FEV1/FVC) ratios (Mann–Whitney p-value 
= 0.52).
Vital capacity and diffusion capacity of lung for carbon monoxide 
(DLCO) were not evaluated as outcome measures in this study.
DISCuSSIon
The data from our study confirms a significant difference in 
dose–volume histograms between anatomic (defined on CT) 
and perfused lung (defined on perfusion SPECT) volumes. This 
is partly explained by technical differences in the acquisition 
of lung volume between the techniques (CT in moderate deep 
inspiration and SPECT in free-breathing), but shows the poten-
tial for using perfusion volumes as an independent “organ-at-
risk” when determining radiotherapy dose scheduling.
The differences in RT dose to anatomic and perfused lung are 
in keeping with prior reports, where the feasibility of radiation 
dose reduction to perfused lung has been demonstrated.9,26–29 
By retrospectively optimizing RT plans with reference to SPECT 
perfusion data, one study demonstrated that the greatest dose 
reduction to perfused lung could be achieved for patients in 
whom perfusion defects adjacent to tumour provided a poten-
tial window for RT delivery, whereas for patients with irregular 
perfusion scattered throughout both lungs, dose reduction to 
perfused lung was less achievable.15 The volume of perfused lung 
has also been shown to decrease 1, 2 and 3 weeks after receipt of 
15 Gy, indicating that SPECT biomarkers can alert the physician 
to the likelihood of symptomatic radiation pneumonitis.30
Our data also demonstrates that the low integral dose (10–20 Gy) 
to background lung, defined on either anatomic or by perfusion 
scans, are the most important dose-scheduling determinants of 
subsequent decline in FEV1. Therefore, constraining this low 
integral dose would have the single greatest preserving effect on 
post-therapy lung function. Prior reports have shown a weak 
correlation between SPECT-based mean perfusion-weighted 
lung dose and impairment of both FEV1 and Transfer factor 
diffusing capacity for carbon monoxide.18 Although no random-
ized controlled trials have yet investigated ability of SPECT perfu-
sion-based RT planning to improve clinical outcome, several 
observational reports have confirmed its predictive capacity in 
this regard.9,14–18,31,32 Furthermore, the MLD to anatomic but 
not perfused lung in our study was also significantly higher in 
the deteriorating FEV1 group and is in keeping with data from 
other groups.33 It may well be that irradiating areas of lung 
that were under the p20 perfusion threshold (but nonetheless 
included in the anatomic volume) also affected adverse respira-
tory outcomes.
The lack of significant difference in our cohort between those 
classified with or without early phase "radiation pneumo-
nitis" on CTCAE was surprising, in view of data from other 
groups.7,14,31 This is possibly attributable to the fact that only 
4 of 40 patients in this study experienced significant "radiation 
pneumonitis" in the early phase. Farr et al and Hoover et al who 
showed that including perfused rather than anatomic lung as an 
"organ-at-risk" improved the ability to predict adverse CTCAE 
outcome, the proportion of patients with "RALI" was higher in 
their cohorts (25/58 or 43% and 7/19 = 37% of patients respec-
tively).7,31 This could in part be due to the longer follow-up 
period in their studies (1, 3, 6, 9 and 12 months). However, even 
with all follow-up time-points for our cohort included (1, 3, 6, 
9, 12, 15, 18, 24 months), only 6/44 patients (14%) experienced 
significant "RALI." As the treatment regimens were equivalent 
between their datasets and ours (60–66 Gy in 2 Gy fractions), 
this discrepancy highlights possible differences between institu-
tions in either dose optimization technique or clinical thresholds 
for grading CTCAE v. 3.0.
From our study, it is noteworthy that the percentage of anatomic 
lung (but not perfused lung) receiving higher radiation doses (40 
and 50 Gy) provided the best predictor of RALI as defined by 
CTCAE. This suggests that the radiological changes which influ-
ence CTCAE score are likely to be the result of the focal high doses 
delivered to lung surrounding tumour, whereas small airways 
inflammation that impacts FEV1 is radiologically “invisible.” 
In line with these findings, ΔFEV1 and CTCAE adverse grade 
had no relationship in our analysis. Although prior studies have 
used CTCAE, spirometry or sequential post RT SPECT perfu-
sion scans separately as outcome measures following RT,7,31,33 
our data records multiple outcome measures in the same study 
population, which gives an assessment of overall morbidity.
The main limitation of this work arises due to intrinsic anatomic 
mis-registration between the free-breathing SPECT acquisition 
and the inspiratory RT planning scans. Free-breathing, perfusion 
volumes often failed to contact the diaphragms when overlaid 
on the RT planning volumes, leading to a systematic shift of the 
perfused compared with the anatomic dose–volume histogram 
data. The image analysis methods used did not adjust for this. In 
future, performing a deformable image registration between two 
sets of CT images (one acquired contemporaneously with the 
SPECT imaging and the other acquired at RT-planning) should 
go some way towards mitigating the different levels of inspiration 
between the techniques.
Figure 4. ROC curve of the anatomic lung volume receiving 50 
Gy for predicting RALI as assessed by worst CTCAE score at a 
3 or 6 month time-point after radiotherapy. CTCAE,Common 
Toxic Criteria for Adverse Events; RALI, radiation-associated 
lunginjury; ROC, receiver operating characteristic.
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These results confirm that the fractional volume (anatomic or 
perfused) of lung that receives >20 Gy differs between patients 
with subsequent decline in FEV1 but that only the fractional 
volume of anatomic lung receiving >50 Gy influences the devel-
opment of RALI as assessed by CTCAE. In patients in whom 
lung function is limited at the outset, consideration must 
therefore be given to the percentage of anatomic and perfused 
lung receiving low doses of radiation. Adding SPECT perfu-
sion imaging as an adjunct to standard CT-based anatomical 
volumes has the potential to refine RT dose–volume schedules, 
and to further mitigate RT-induced morbidity.
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